Immunosuppressive agents are associated with peptic ulcer bleeding

  • Authors:
    • Minoru Tomizawa
    • Fuminobu Shinozaki
    • Rumiko Hasegawa
    • Yoshinori Shirai
    • Yasufumi Motoyoshi
    • Takao Sugiyama
    • Shigenori Yamamoto
    • Naoki Ishige
  • View Affiliations

  • Published online on: March 9, 2017     https://doi.org/10.3892/etm.2017.4214
  • Pages: 1927-1931
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Peptic ulcer bleeding can be fatal. Non‑steroidal anti-inflammatory drugs (NSAIDs), corticosteroids and immunosuppressive agents are administered for long‑term usage. The present study assessed the association between peptic ulcer bleeding and administration of NSAIDs, corticosteroids and immunosuppressive agents. Furthermore, the efficacy of lowering the risk of peptic ulcer bleeding with proton pump inhibitors (PPI) and histamine 2 receptor antagonists (H2RA) was evaluated. Medical records were retrospectively analyzed for patients subjected to an upper gastrointestinal (GI) endoscopy performed at the National Hospital Organization Shimoshizu Hospital (Yotsukaido, Japan) from October 2014 to September 2015. During this period, a total of 1,023 patients underwent an upper GI endoscopy. A total of 1,023 patients, including 431 males (age, 68.1±12.9 years) and 592 females (age, 66.4±12.3 years), who had been administered NSAIDs, corticosteroids, immunosuppressive agents, PPIs and H2RAs, were respectively enrolled. Endoscopic findings of the patients were reviewed and their data were statistically analyzed. Logistic regression analysis was used to determine the odds ratio of peptic ulcer bleeding for each medication; immunosuppressive agents had an odds ratio of 5.83, which was larger than that for NSAIDs (4.77). The Wald test was applied to confirm the correlation between immunosuppressive agents and peptic ulcer bleeding. Furthermore, χ2 tests were applied to the correlation between peptic ulcer bleeding and administration of PPIs or H2RAs. Immunosuppressive agents had the largest χ2, and the P‑value was 0.03. Administration of PPIs was significantly correlated with non‑peptic ulcer bleeding (P=0.02); furthermore, a tendency toward non‑peptic ulcer bleeding with administration of H2RA was indicated, but it was not statistically significant (P=0.12). In conclusion, immunosuppressive agents were correlated with peptic ulcer bleeding and PPIs were effective at lowering the risk of peptic ulcer bleeding.

Introduction

Peptic ulcers comprise gastric and duodenal ulcers. Complications of peptic ulcers include bleeding, perforation and obstruction (1). Bleeding is a major problem of peptic ulcers, as it is at times fatal (2). Peptic ulcer bleeding is diagnosed and treated by upper gastrointestinal (GI) endoscopy (3). Known causes of peptic ulcer bleeding are the long-term administration of non-steroidal anti-inflammatory drugs (NSAIDs), anti-platelet agents, anti-coagulants and infection with Helicobacter pylori (4).

NSAIDs are commonly used for rheumatic diseases and persistent pain due to orthopedic diseases (5,6). Rheumatic diseases have an autoimmune basis and affect connective tissue (6,7). This inflammation damages tissue and impairs the patient's quality of life (8,9). To suppress the autoimmune basis of the disease, corticosteroids and immunosuppressive agents are used (1012). Tumor necrosis factor a blockers, biological modifiers, are also used to suppress the autoimmune response (13,14). It is well known that corticosteroids trigger peptic ulcer bleeding by making the gastric mucosa susceptible to ulceration by gastric acid (1517). However, the correlation between immunosuppressive agents and upper GI bleeding has remained to be determined.

For the prevention of peptic ulcer bleeding, proton pump inhibitors (PPIs) and histamine 2 receptor antagonists (H2RAs) are used (18). PPIs and H2RAs increase the pH of gastric acid, prevent damage of the gastric mucosa and promote the healing of peptic ulcers (19,20). PPIs are superior to H2RAs in preventing peptic ulcer bleeding due to stress in patients in intensive care (21). However, the efficacy of the prevention of peptic ulcer bleeding has remained elusive in patients with long-term administration of PPIs or H2RAs.

In the present study, the association between peptic ulcer bleeding and administration of NSAIDs, corticosteroids and immunosuppressive agents was analyzed in patients with rheumatic or orthopedic diseases. Furthermore, the prevention of peptic ulcer bleeding by PPIs and H2RAs was evaluated.

Materials and methods

Ethics statement

The present study was approved by the National Hospital Organization Shimoshizu Hospital Ethics Committee (Yotsukaido, Japan). It was not considered a clinical trial, as the procedures were performed as part of a routine clinical practice. Written informed consent for inclusion in the study was waived. Patient records were anonymized and retrospectively analyzed. Written informed consent was obtained from all patients who were subjected to upper GI endoscopy.

Patients

Medical records were retrospectively analyzed for patients subjected to upper GI endoscopy performed at the National Hospital Organization Shimoshizu Hospital (Yotsukaido, Japan) from October 2014 to September 2015. During this period, a total of 1,023 patients underwent an upper GI endoscopy for the investigation of anemia, abdominal pain or tarry stool. In addition, certain patients underwent upper GI endoscopy for screening. The cohort comprised 431 males (age, 68.1±12.9 years) and 592 females (age, 66.4±12.3 years).

Study design

The 1,023 patents were analyzed with regard to administration of NSAIDs, corticosteroids, immunosuppressive agents, PPIs and H2RAs. Endoscopic findings were reviewed in the 1,023 patients; these data were analyzed statistically. For patients with bleeding from peptic ulcers, results of urea breath test and past history of peptic ulcers were reviewed. The urea breath test was performed to detect Helicobacter pylori infection and outsourced to LSI Medience Corp. (Tokyo, Japan).

Medication

The cohort of the present study had received immunosuppressive agents, including methotrexate and tacrolimus, as well as biological agents, including infliximab, etanercept, adalimumab and golimumab. Corticosteroids and immunosuppressive agents were used for rheumatic diseases, such as rheumatoid arthritis and systemic lupus erythematosus. NSAIDs were administered to patients with lumbar discopathy and deformation spondylosis. Table I shows the number and ratio of patients administered each type of drug.

Table I.

Number of patients taking each medication.

Table I.

Number of patients taking each medication.

MedicationNumber of patientsRatio, %
NSAIDs  19  1.85
Corticosteroids  92  8.99
Immunosuppressive agents  30  2.93
PPI11810.51
H2RA  30  2.93

[i] NSAIDs, nonsteroidal anti-inflammatory drugs; PPI, proton pump inhibitor; H2RA, histamine type 2 receptor antagonist.

Upper GI endoscopy

Patients were subjected to upper GI endoscopy for screening, or investigation of abdominal symptoms or anemia. The endoscopic devices used were the GIF-N260H, GIF-XP260NS, GIF-PG260, GIF-XQ260 and GIF-Q260 (Olympus, Tokyo, Japan). A gastric or duodenal ulcer was considered to be a peptic ulcer. Bleeding from a peptic ulcer was restricted to a spurting vessel, an oozing vessel, a visible vessel or a clot, according to the Forrest classification system (22). Table II shows the diagnosis of patients with peptic ulcer bleeding. Seventeen and two patients were diagnosed with bleeding from gastric and duodenal ulcers, respectively.

Table II.

Diagnosis of upper gastrointestinal bleeding from peptic ulcers by endoscopy.

Table II.

Diagnosis of upper gastrointestinal bleeding from peptic ulcers by endoscopy.

Peptic ulcer or non-peptic ulcerDiagnosisNumber of patients
Peptic ulcerGastric ulcer17
Duodenal ulcer  2
Total 19
Statistical analysis

Logistic regression analysis was used to determine the odds ratio and 95% confidence interval of peptic ulcer bleeding for each medication. The Wald test was applied to analyze the statistical significance of the correlation of peptic ulcer bleeding and medication (23). Chi-square tests were applied to analyze the correlation between peptic ulcer bleeding and administration of PPIs or H2RAs. P<0.05 was considered to indicate a statistically significant difference. JMP 10.0.2 software (SAS Institute, Cary, CA, USA) was used for statistical analysis.

Results

Patient characteristics

Table III shows the characteristics of patients with bleeding from peptic ulcers. The patients had been subjected to monotreatment with NSAIDs, immunosuppressive agents or corticosteroid, but not their combination. Four patients were subjected to the urea breath test, one of which was positive and had a history of peptic ulcer.

Table III.

Characteristics of patients with bleeding from peptic ulcers.

Table III.

Characteristics of patients with bleeding from peptic ulcers.

Patient no.DiagnosisGenderAgeDiseaseNSAIDsImmunosuppressive agents CorticosteroidsHistory of peptic ulcersH. pylori
  1GUF79Lumbar discopathy(+)(−)(−)(−)NA
  2GUM73RA(−)(−)(+)(−)NA
  3GUM73RA(−)(−)(+)(−)NA
  4GUM73RA(−)(−)(+)(−)NA
  5GUF66(−)(−)(+)(−)(−)NA
  6GUF67RA(−)(+)(−)(−)NA
  7GUM22DMD(−)(−)(−)(−)NA
  8GUM78(−)(−)(−)(−)(−)NA
  9GUM72(−)(−)(−)(−)(+)NA
10GUM72(−)(−)(−)(−)(+)NA
11GUM84(−)(−)(−)(−)(−)NA
12GUM71(−)(−)(−)(−)(−)NA
13GUF70(−)(−)(−)(−)(−)NA
14GUM69(−)(−)(−)(−)(+)(+)
15GUF84(−)(−)(−)(−)(−)NA
16GUF87(−)(−)(−)(−)(−)NA
17GUF70(−)(−)(−)(−)(−)(+)
18DGF42(−)(−)(−)(−)(−)(−)
19DGF42(−)(−)(−)(−)(−)(−)

[i] NSAIDs, non-steroidal anti-inflammatory drugs; GU, gastric ulcer; DG, duodenal ulcer; M, male; F, female; RA, rheumatoid arthritis; DMD, Duchenne muscular dystrophy; NA, not analyzed; H. pylori, Helicobacter pylori.

Effect of the medication with regard to bleeding

To calculate the odds ratios for various medication types with regard to peptic ulcer bleeding, logistic regression analysis was used (Table IV). The odds ratio of immunosuppressive agents was 5.83, which was larger than that of NSAID (4.77). It was found that among the different medications, immunosuppressive agents had the strongest correlation with peptic ulcer bleeding.

Table IV.

Logistic regression analysis of the relationship between medication and bleeding from peptic ulcers.

Table IV.

Logistic regression analysis of the relationship between medication and bleeding from peptic ulcers.

MedicationOdds ratio95% CI
NSAIDs4.770.25–26.25
Corticosteroids2.770.62–9.62
Immunosuppressive agents5.830.88–22.88

[i] CI, confidence interval, NSAIDs, nonsteroidal anti-inflammatory drugs.

Confirmation of the association between medication and bleeding

To confirm the association between immunosuppressive agents and peptic ulcer bleeding, the Wald test was applied (Table V). Immunosuppressive agents had the largest χ2 result (4.98) and P=0.03 (Table V).

Table V.

Wald test of the association between medication and bleeding from peptic ulcers.

Table V.

Wald test of the association between medication and bleeding from peptic ulcers.

Medicationχ2P-value
NSAIDs2.120.15
Corticosteroids2.370.12
Immunosuppressive agents4.980.03

[i] NSAIDs, non-steroidal anti-inflammatory drugs.

Proton-pump inhibitor and bleeding

To reveal the correlation between PPIs and peptic ulcer bleeding, a χ2 test was applied (Table VI). Administration of PPIs was significantly correlated with non-peptic ulcer bleeding (P=0.02).

Table VI.

Correlation between PPI intake and bleeding from peptic ulcers.

Table VI.

Correlation between PPI intake and bleeding from peptic ulcers.

Peptic ulcer bleeding (P=0.02)

PPI intakeNegative, n (%)Positive, n (%)Total
Yes892 (87.19)13 (1.27)905 (88.47%)
No112 (10.95)6 (0.59)118 (11.53%)
Total1,004 (98.14)19 (1.86)1,023 (100%)

[i] PPI, proton pump inhibitor. P=0.02 compares PPI intake and no PPI treatment in peptic ulcer bleeding.

Histamine type 2 receptor antagonist and bleeding

To analyze the correlation between H2RAs and peptic ulcer bleeding, a χ2 test was applied (Table VII). A tendency toward non-peptic ulcer bleeding with administration of H2Ras was identified; however, it was not statistically significant (P=0.12).

Table VII.

Correlation between H2RA intake and bleeding from peptic ulcers.

Table VII.

Correlation between H2RA intake and bleeding from peptic ulcers.

Peptic ulcer bleeding (P=0.12)

H2RA intakeNegative, n (%)Positive, n (%)Total
Yes976 (95.41)17 (1.66)993 (97.07%)
No28 (2.73)2 (0.2)30 (2.93%)
Total1004 (98.14)19 (1.86)1023 (100%)

[i] H2RA, histamine H2 receptor antagonist. P=0.12 compares H2RA intake and no H2RA treatment in peptic ulcer bleeding.

Discussion

Case reports and case series have documented the use of immunosuppressive agents to treat patients with peptic ulcers (2426). However, studies assessing the possible association between the administration of immunosuppressive agents and peptic ulcer bleeding are currently lacking. To answer this question, the present case findings provided novel evidence that immunosuppressive agent use is significantly correlated with peptic ulcer bleeding. Although the mechanisms by which immunosuppressive agent use may be correlated with peptic ulcer bleeding is elusive, it is possible that these agents cause bleeding by inhibiting ulcer healing (26). The results of the present study are clinically important, as they are relevant to ensuring patient safety, with peptic ulcer bleeding being one reason for the discontinuation of immunosuppressive agents (27). Further studies with additional patients are therefore warranted to confirm these results.

NSAIDs and corticosteroids cause gastric and duodenal ulcers, and increase the risk of upper GI bleeding. In previous studies, NSAIDs and corticosteroids were rated to not pose any risk for peptic ulcer bleeding (28,29). In the present study, NSAIDs and corticosteroids showed no correlation with upper GI bleeding. The results of the present study are therefore consistent with those of previous ones. However, it is premature to conclude that NSAIDs and corticosteroids are less hazardous. One reason is that in the present study, the number of patients treated with NSAIDs and corticosteroids was relatively small. Peptic ulcer bleeding is still fatal in certain patients, such as the elderly (30). Precautions should be taken for patients treated with NSAIDs and/or corticosteroids to avoid upper GI bleeding.

PPIs are effective for reducing peptic ulcer bleeding (31). They are more effective at lowering the risk of upper GI peptic ulcer bleeding than H2RAs (32). In the present study, PPIs significantly lowered the risk of peptic ulcer bleeding. Therefore, the results of the present study were consistent with those of previous ones. PPIs are frequently used in combination with NSAIDs or corticosteroids to lower the risk of peptic ulcer bleeding (10,33). Likewise, PPIs may lower the risk of peptic ulcer bleeding associated with immunosuppressive agents. However, PPIs represent a risk factor for bleeding from the small intestine, hip fracture and cardiac events (34,35). It is therefore recommended that long-term use of PPIs is avoided (36). With this regard, H2RAs may be recommended for long-term administration to prevent peptic ulcer bleeding.

A major limitation is that the present study was based on a relatively small number of patients. This may explain why no correlation was found between NSAIDs, corticosteroids, immunosuppressive agents and upper GI bleeding. In future studies, a larger number of patients should be enrolled and studied.

In conclusion, the present study revealed that immunosuppressive agents were correlated with peptic ulcer bleeding. However, PPIs were effective at lowering the risk of peptic ulcer bleeding.

References

1 

Milosavljevic T, Kostić-Milosavljević M, Jovanović I and Krstić M: Complications of peptic ulcer disease. Dig Dis. 29:491–493. 2011. View Article : Google Scholar : PubMed/NCBI

2 

Leontiadis GI, Molloy-Bland M, Moayyedi P and Howden CW: Effect of comorbidity on mortality in patients with peptic ulcer bleeding: Systematic review and meta-analysis. Am J Gastroenterol. 108:331–345; quiz 346. 2013. View Article : Google Scholar : PubMed/NCBI

3 

Kim SY, Hyun JJ, Jung SW and Lee SW: Management of non-variceal upper gastrointestinal bleeding. Clin Endosc. 45:220–223. 2012. View Article : Google Scholar : PubMed/NCBI

4 

Huang TC and Lee CL: Diagnosis, treatment, and outcome in patients with bleeding peptic ulcers and Helicobacter pylori infections. Biomed Res Int. 2014:6581082014. View Article : Google Scholar : PubMed/NCBI

5 

Makris UE, Abrams RC, Gurland B and Reid MC: Management of persistent pain in the older patient: A clinical review. JAMA. 312:825–836. 2014. View Article : Google Scholar : PubMed/NCBI

6 

Bahadur S, Keshri L and Pathak K: Adverse drug reactions and safety considerations of NSAIDs: Clinical analysis. Curr Drug Saf. 6:310–317. 2011. View Article : Google Scholar : PubMed/NCBI

7 

Grateau G, Hentgen V, Stojanovic KS, Jéru I, Amselem S and Steichen O: How should we approach classification of autoinflammatory diseases? Nat Rev Rheumatol. 9:624–629. 2013. View Article : Google Scholar : PubMed/NCBI

8 

da Mota LM, Laurindo IM and dos Santos Neto LL: Prospective evaluation of the quality of life in a cohort of patients with early rheumatoid arthritis. Rev Bras Reumatol. 50:249–261. 2010.(In English, Portuguese). PubMed/NCBI

9 

Radner H, Yoshida K, Mjaavatten MD, Aletaha D, Frits M, Lu B, Iannaccone C, Shadick N, Weinblatt M, Hmamouchi I, et al: Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. Semin Arthritis Rheum. 45:167–173. 2015. View Article : Google Scholar : PubMed/NCBI

10 

van der Goes MC, Jacobs JW and Bijlsma JW: The value of glucocorticoid co-therapy in different rheumatic diseases-positive and adverse effects. Arthritis Res Ther. 16:(Suppl 2). S22014. View Article : Google Scholar : PubMed/NCBI

11 

Goodman SM, Cronstein BN and Bykerk VP: Outcomes related to methotrexate dose and route of administration in patients with rheumatoid arthritis: A systematic literature review. Clin Exp Rheumatol. 33:272–278. 2015.PubMed/NCBI

12 

Motomura H, Matsushita I, Seki E, Mine H and Kimura T: Inhibitory effect of tacrolimus on progression of joint damage in patients with rheumatoid arthritis. Int J Rheum Dis. 17:749–754. 2014. View Article : Google Scholar : PubMed/NCBI

13 

Mok CC: Rituximab for the treatment of rheumatoid arthritis: An update. Drug Des Devel Ther. 8:87–100. 2014.

14 

Tanaka Y and Hirata S: Intensive intervention can lead to a treatment holiday from biological DMARDs in patients with rheumatoid arthritis. Drugs. 74:2129–2139. 2014. View Article : Google Scholar : PubMed/NCBI

15 

Gralnek IM, Dumonceau JM, Kuipers EJ, Lanas A, Sanders DS, Kurien M, Rotondano G, Hucl T, Dinis-Ribeiro M, Marmo R, et al: Diagnosis and management of nonvariceal upper gastrointestinal hemorrhage: European society of gastrointestinal endoscopy (ESGE) guideline. Endoscopy. 47:a1–a46. 2015. View Article : Google Scholar : PubMed/NCBI

16 

Niv Y, Boltin D, Halpern M, Cohen M, Levi Z, Vilkin A, Morgenstern S, Manugian V, St Lawrence E, Gagneux P, et al: Membrane-bound mucins and mucin terminal glycans expression in idiopathic or Helicobacter pylori, NSAID associated peptic ulcers. World J Gastroenterol. 20:14913–14920. 2014. View Article : Google Scholar : PubMed/NCBI

17 

Bandyopadhyay U, Biswas K, Bandyopadhyay D, Ganguly CK and Banerjee RK: Dexamethasone makes the gastric mucosa susceptible to ulceration by inhibiting prostaglandin synthetase and peroxidase-two important gastroprotective enzymes. Mol Cell Biochem. 202:31–36. 1999. View Article : Google Scholar : PubMed/NCBI

18 

Nakashima S, Ota S, Arai S, Yoshino K, Inao M, Ishikawa K, Nakayama N, Imai Y, Nagoshi S and Mochida S: Usefulness of anti-ulcer drugs for the prevention and treatment of peptic ulcers induced by low doses of aspirin. World J Gastroenterol. 15:727–731. 2009. View Article : Google Scholar : PubMed/NCBI

19 

Kyaw MH and Chan FK: Pharmacologic options in the management of upper gastrointestinal bleeding: Focus on the elderly. Drugs Aging. 31:349–361. 2014. View Article : Google Scholar : PubMed/NCBI

20 

Tuskey A and Peura D: The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage. Arthritis Res Ther. 15:(Suppl 3). S62013. View Article : Google Scholar : PubMed/NCBI

21 

Alhazzani W, Alenezi F, Jaeschke RZ, Moayyedi P and Cook DJ: Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: A systematic review and meta-analysis. Crit Care Med. 41:693–705. 2013. View Article : Google Scholar : PubMed/NCBI

22 

Forrest JA, Finlayson ND and Shearman DJ: Endoscopy in gastrointestinal bleeding. Lancet. 2:394–397. 1974. View Article : Google Scholar : PubMed/NCBI

23 

Hellmann SS, Njor SH, Lynge E, von Euler-Chelpin M, Olsen A, Tjønneland A, Vejborg I and Andersen ZJ: Body mass index and participation in organized mammographic screening: A prospective cohort study. BMC Cancer. 15:2942015. View Article : Google Scholar : PubMed/NCBI

24 

Smith LA, Gangopadhyay M and Gaya DR: Catastrophic gastrointestinal complication of systemic immunosuppression. World J Gastroenterol. 21:2542–2545. 2015. View Article : Google Scholar : PubMed/NCBI

25 

Prueksapanich P, Pittayanon R, Avihingsanon Y and Rerknimitr R: Persistent duodenal ulcers bleeding in postkidney transplant patient treated by infliximab. BMJ Case Rep. 2013:bcr20130090252013. View Article : Google Scholar : PubMed/NCBI

26 

Smith AD, Bai D, Marroquin CE, Tuttle-Newhall JE, Desai DM, Collins BH, Muir A, Kuo PC, McHutchison J and Rockey DC: Gastrointestinal hemorrhage due to complicated gastroduodenal ulcer disease in liver transplant patients taking sirolimus. Clin Transplant. 19:250–254. 2005. View Article : Google Scholar : PubMed/NCBI

27 

Cho SK, Sung YK, Choi CB and Bae SC: Impact of comorbidities on TNF inhibitor persistence in rheumatoid arthritis patients: An analysis of Korean national health insurance claims data. Rheumatol Int. 32:3851–3856. 2012. View Article : Google Scholar : PubMed/NCBI

28 

Ahsberg K, Höglund P, Kim WH and von Holstein CS: Impact of aspirin, NSAIDs, warfarin, corticosteroids and SSRIs on the site and outcome of non-variceal upper and lower gastrointestinal bleeding. Scand J Gastroenterol. 45:1404–1415. 2010. View Article : Google Scholar : PubMed/NCBI

29 

Narum S, Westergren T and Klemp M: Corticosteroids and risk of gastrointestinal bleeding: A systematic review and meta-analysis. BMJ Open. 4:e0045872014. View Article : Google Scholar : PubMed/NCBI

30 

Lau JY, Barkun A, Fan DM, Kuipers EJ, Yang YS and Chan FK: Challenges in the management of acute peptic ulcer bleeding. Lancet. 381:2033–2043. 2013. View Article : Google Scholar : PubMed/NCBI

31 

Trawick EP and Yachimski PS: Management of non-variceal upper gastrointestinal tract hemorrhage: Controversies and areas of uncertainty. World J Gastroenterol. 18:1159–1165. 2012. View Article : Google Scholar : PubMed/NCBI

32 

Mo C, Sun G, Wang YZ, Lu ML and Yang YS: PPI versus histamine H2 receptor antagonists for prevention of upper gastrointestinal injury associated with low-dose aspirin: Systematic review and meta-analysis. PLoS One. 10:e01315582015. View Article : Google Scholar : PubMed/NCBI

33 

Zullo A, Hassan C, Campo SM and Morini S: Bleeding peptic ulcer in the elderly: Risk factors and prevention strategies. Drugs Aging. 24:815–828. 2007. View Article : Google Scholar : PubMed/NCBI

34 

Marlicz W, Loniewski I, Grimes DS and Quigley EM: Nonsteroidal anti-inflammatory drugs, proton pump inhibitors and gastrointestinal injury: Contrasting interactions in the stomach and small intestine. Mayo Clin Proc. 89:1699–1709. 2014. View Article : Google Scholar : PubMed/NCBI

35 

Ament PW, Dicola DB and James ME: Reducing adverse effects of proton pump inhibitors. Am Fam Physician. 86:66–70. 2012.PubMed/NCBI

36 

Shin S: Evaluation of costs accrued through inadvertent continuation of hospital-initiated proton pump inhibitor therapy for stress ulcer prophylaxis beyond hospital discharge: A retrospective chart review. Ther Clin Risk Manag. 11:649–657. 2015. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

May-2017
Volume 13 Issue 5

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tomizawa M, Shinozaki F, Hasegawa R, Shirai Y, Motoyoshi Y, Sugiyama T, Yamamoto S and Ishige N: Immunosuppressive agents are associated with peptic ulcer bleeding. Exp Ther Med 13: 1927-1931, 2017
APA
Tomizawa, M., Shinozaki, F., Hasegawa, R., Shirai, Y., Motoyoshi, Y., Sugiyama, T. ... Ishige, N. (2017). Immunosuppressive agents are associated with peptic ulcer bleeding. Experimental and Therapeutic Medicine, 13, 1927-1931. https://doi.org/10.3892/etm.2017.4214
MLA
Tomizawa, M., Shinozaki, F., Hasegawa, R., Shirai, Y., Motoyoshi, Y., Sugiyama, T., Yamamoto, S., Ishige, N."Immunosuppressive agents are associated with peptic ulcer bleeding". Experimental and Therapeutic Medicine 13.5 (2017): 1927-1931.
Chicago
Tomizawa, M., Shinozaki, F., Hasegawa, R., Shirai, Y., Motoyoshi, Y., Sugiyama, T., Yamamoto, S., Ishige, N."Immunosuppressive agents are associated with peptic ulcer bleeding". Experimental and Therapeutic Medicine 13, no. 5 (2017): 1927-1931. https://doi.org/10.3892/etm.2017.4214